TRIP Clinical Trial: Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson’s disease

Cognitive impairment and dementia are a top concern for people living with Parkinson’s disease (PD). The TRIP study explores a potential treatment for mild memory impairment with the overall aim of reducing dementia risk in Parkinson’s disease. This study is registered at: clinicaltrials.gov/ct2/show/NCT04643327

Contact

Dana Pourzinal

Email: pd.research@uq.edu.au

Phone: (07) 3346 5028